Search
Telmisartan
go.drugbank.com/drugs/DB00966ApprovedInvestigationalGenerally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular … smooth muscle, ultimately leading to a reduction in arterial blood pressure.
Mixtures: TELMISARTAN E IDROCLOROTIAZIDE EG, TELMISARTAN E IDROCLOROTIAZIDE EGCategories: Agents Acting on the Renin-Angiotensin SystemBupropion
go.drugbank.com/drugs/DB01156ApprovedInvestigationalMore specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT). … [F4624] When used in combination with [naltrexone] in the marketed product ContraveⓇ for chronic weight management, the two components are thought to have effects on areas of the brain involved in the
Products: ODRANAL® 150 MG TABLETASRECUBIERTAS DE LIBERACION PROLONGADAAcetarsol
go.drugbank.com/drugs/DB13268ApprovedWithdrawnIt has been canceled and withdrawn from the market since August 12, 1997.[L1113] … Acetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties.
Febuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigational[A39743] In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. … The manufacturer and the FDA advise health professionals to limit the use of febuxostat to second-line therapy in patients who have inadequate response or intolerance to allopurinol, and to avoid the use
Aducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard … [L34393] In January 2024, Biogen announced that the development and commercialization of aducanumab will be discontinued to prioritize the marketing of [lecanemab], another drug approved for the treatment
Aminohippuric acid
go.drugbank.com/drugs/DB00345ApprovedInvestigationalWithdrawnThe glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]
Naxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigational[A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. … [L24454] This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies,[A224604] making
Ziconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigational[L13389] To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.[A202835] … [A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.
Famtozinameran
go.drugbank.com/drugs/DB17088ApprovedInvestigational[L43917] As of November 2022, it is the primary circulating variant of concern according to the World Health Organization. … [L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta).
Samidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigationalmay be expected to ameliorate these negative effects. … [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™